A Phase 1, Open-Label, Single-Dose Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941.
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2010
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- 06 Oct 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
- 06 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Sep 2010 New trial record